Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of type 2 diabetes mellitus prior to informed consent~2. Male and female patients on diet and exercise regimen who are drug-naive, defined as absence of any oral antidiabetic therapy for 12 weeks prior to randomization~3. HbA1c \>=7.5% and \<= 12% (\>=58.5 mmol/mol and \<=107.7 mmol/mol)~4. Body Mass Index (BMI) \<= 45 kg/m2 at screening~Exclusion criteria:~1. Uncontrolled hyperglycemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second laboratory measurement (not on the same day)~2. Any antidiabetic drug within 12 weeks prior to randomization~3. Impaired renal function, defined as estimated creatinine clearance rate (eCCr) \<60 ml/min (Cockcroft-Gault formula) as determined during screening and/or run-in period~4. Contraindications to metformin according to the local label

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin low dose qd (Type: EXPERIMENTAL): Empagliflozin low dose once daily
- Empagliflozin high dose qd (Type: EXPERIMENTAL): Empagliflozin high dose once daily
- OL empa high dose + met 1000 mg bid (Type: EXPERIMENTAL): Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study.
- Empagliflozin low dose + met 500 mg bid (Type: EXPERIMENTAL): Empagliflozin low dose split twice daily + metformin 500 mg twice daily
- Empagliflozin low dose + met 1000 mg bid (Type: EXPERIMENTAL): Empagliflozin low dose split twice daily + metformin 1000 mg twice daily
- Empagliflozin high dose + met 500 mg bid (Type: EXPERIMENTAL): Empagliflozin high dose split twice daily + metformin 500 mg twice daily
- Empagliflozin high dose + met 1000mg bid (Type: EXPERIMENTAL): Empagliflozin high dose split twice daily + metformin 1000 mg twice daily
- Metformin 500 mg bid (Type: EXPERIMENTAL): Metformin 500 mg twice daily
- Metformin 1000 mg bid (Type: EXPERIMENTAL): Metformin 1000 mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).